Enterprise value to revenue forward of Novanta Inc. - Tangible Equity – NASDAQ:NOVTU
The article provides the title and basic identification of "Enterprise value to revenue forward of Novanta Inc. - Tangible Equity." It is listed under the NASDAQ stock market with the symbol NOVTU. The content primarily consists of navigation and footer information from the TradingView platform, with no actual financial data or article text provided beyond the title itself.
Should Novanta’s New US$338 Million Shelf Offering Plan Reframe How Investors View NOVT’s Capital Strategy?
Novanta Inc. has filed a shelf registration for up to US$337.61 million in common shares, providing flexibility for future equity issuance. This move allows the company to strengthen its capital structure and fund acquisitions, such as Riverpoint Medical, while investors consider potential dilution risks and the company's ability to drive earnings growth from precision technologies despite market softness. The filing emphasizes the importance of successful acquisition integration and managing trade headwinds.
Should Novanta’s New US$338 Million Shelf Offering Plan Reframe How Investors View NOVT’s Capital Strategy?
Novanta Inc. recently filed a shelf registration to offer up to US$337.61 million in common shares, providing flexibility for future equity issuance. This move could impact Novanta's capital structure and dilute existing shares, especially as the company focuses on growth through acquisitions amidst flat organic momentum and segment softness. Investors should consider how this potential financing tool, alongside a recent credit agreement amendment for the Riverpoint Medical acquisition, aligns with the company's broader strategy and its ability to navigate market challenges.
Form 144 Novanta For: 2 July By Investing.com
This article from Investing.com reports on Form 144 for Novanta, filed for July 2nd. It's a very brief news item, likely indicating an insider's intent to sell restricted stock in Novanta Inc. (NOVT). The content emphasizes the filing date and the company concerned.
Form 144 Novanta For: 2 July By Investing.com
The article "Form 144 Novanta For: 2 July" from Investing.com is a brief news headline. It indicates that a Form 144 was filed for Novanta (NOVT) on July 2nd. The content primarily consists of navigation, advertisements, market data, and unrelated news headlines, with the actual article content being very sparse.
Matthijs Glastra sells shares; Novanta (NASDAQ: NOVT) Form 144 notice
Matthijs Glastra, an affiliate of Novanta (NASDAQ: NOVT), has filed a Form 144 notice indicating proposed sales of common stock. The filing details several recent sales by Glastra, including 7,500 shares on May 12, 2026, for proceeds of $1,125,000, and several Restricted Stock Unit grants. This Form 144 serves as a routine disclosure for affiliate resales and does not signify a material corporate action or generate proceeds for Novanta itself.
Form S-3ASR Novanta Inc For: 29 June By Investing.com
This article announces the filing of Form S-3ASR by Novanta Inc. for June 29. It briefly highlights the company's stock symbol (NOVT) and its recent performance in the stock market. The content primarily serves as a short notification, with additional market data and popular news articles filling the rest of the page.
NOVT: Selling Stockholders Offer 2.14 Million Shares
Novanta Inc. (NOVT) selling stockholders are offering 2.14 million common shares, though the company itself is not participating and will not benefit from the proceeds. Despite a high P/E ratio of 114.31x and significant insider selling totaling $3.9 million in the last three months, Novanta maintains a strong GF Score of 87/100, driven by excellent financial strength and profitability. Investors are advised to proceed with caution due to the high valuation and insider selling trend.
Novanta Inc. (NASDAQ: NOVT) registers 2.14M shares for resale
Novanta Inc. has registered 2,142,857 common shares for resale, stemming from a private placement in June 2026 where shares were sold at $140.00 each, totaling approximately $300.0 million. The company will not receive any proceeds from these resales, as the funds will go directly to the selling shareholders. This shelf registration allows selling shareholders to offer these shares over time, with specific terms to be detailed in future prospectus supplements.
Enterprise value to EBITDA forward of Novanta Inc. – NASDAQ:NOVT
This article provides financial information for Novanta Inc. (NASDAQ: NOVT), specifically its enterprise value to forward EBITDA. The content is presented within the TradingView platform, showing key financial metrics and disclaimers about data sources.
Analyst Upgrade and Conference Remarks Might Change The Case For Investing In Novanta (NOVT)
Novanta (NOVT) recently received an analyst upgrade to a Zacks Rank #2 (Buy) due to increased optimism regarding its earnings and profit outlook. This coincides with its CFO and COO presenting at the CJS Securities New Ideas Summer Conference, offering insights into growth drivers and operational priorities. The article examines how the upgrade, tied to improving earnings estimates, might impact Novanta's investment narrative, especially concerning its reliance on acquisitions for growth and the risks associated with integration and muted organic demand.
Price to book forward of Novanta Inc. – NASDAQ:NOVT
The article focuses on the "Price to book forward" metric for Novanta Inc. (NASDAQ: NOVT). It appears to be a financial data page from TradingView, providing an overview of this specific valuation ratio for the company over different periods.
Enterprise value to revenue forward of Novanta Inc. – NASDAQ:NOVT
This article focuses on the "Enterprise value to revenue forward" metric for Novanta Inc. (NASDAQ: NOVT). It appears to be a financial data point presented on a trading platform, indicating a specific valuation ratio for the company. The content itself seems to be a data point rather than a detailed analysis.
NOVT Forecast — Price Target — Prediction for 2027
This article provides a forecast for Novanta Inc. (NOVT) stock, including analyst price targets, current stock performance, and financial data. It highlights the stock's recent price movements, its historical highs and lows, and upcoming earnings dates, while emphasizing that the content is not investment advice.
Novanta Inc Units Actuals & Estimates (NASDAQ:NOVTU)
This page on TradingView provides financial actuals and estimates for Novanta Inc. Units (NASDAQ: NOVTU). It allows users to explore reported financial data and analyst estimates across income statements, balance sheets, cash flow statements, and valuation metrics, comparing actual results with various estimates and visualizing trends over time. The platform also offers disclaimers regarding investment advice.
Novanta Inc Actuals & Estimates (NASDAQ:NOVT)
This article provides an overview of Novanta Inc. (NASDAQ: NOVT) stock, including its current price, market capitalization, and historical performance. It also details analyst forecasts, financial actuals versus estimates for earnings and revenue, upcoming earnings dates, and technical analysis ratings.
NOVT Stock Price Prediction 2025-2026 | Novanta Inc Forecast
24/7 Wall St. rates Novanta Inc (NOVT) as a SELL, setting a 12-month target price of $121.70, indicating a 19.94% downside from its current price of $152.00. While an optimistic scenario could see NOVT reach $189.04, a conservative view places the floor at $111.72 due to potential headwinds. The analysis factors in analyst sentiment, growth baselines, sector momentum, earnings, volatility, and price position, and also includes long-term projections through 2031, with a modest average price prediction for 2030.
NOVT Stock Price Prediction 2025-2026 | Novanta Inc Forecast
24/7 Wall St. projects a "SELL" rating for Novanta Inc (NOVT) with a 12-month target price of $121.70, suggesting a 19.94% downside from its current price of $152.00. The analysis considers optimistic and conservative scenarios, projecting potential highs of $189.04 and lows of $111.72, respectively. Despite three Wall Street analysts rating it as "Buy," 24/7 Wall St.'s proprietary model identifies potential headwinds and recommends reducing exposure or awaiting a better entry point.
Novanta to Present at the CJS Securities 26th Annual New Ideas Summer Conference on Thursday, July 9, 2026
Novanta Inc. (Nasdaq: NOVT) announced that its Chief Financial Officer, Robert Buckley, and Chief Operating Officer, Chuck Ravetto, are scheduled to present at the CJS Securities 26th Annual New Ideas Summer Conference on Thursday, July 9, 2026, in White Plains, NY. Novanta is a leading global supplier of core technology solutions for medical, life science, and advanced industrial equipment manufacturers. The company's presentation will highlight its expertise in precision medicine, manufacturing, robotics, and advanced surgery.
Novanta Inc (NOVT) Valuation: PE, PB & Fair Value Analysis
This article provides a valuation analysis of Novanta Inc (NOVT), stating that its current valuation score is 6.69, positioning it 51st out of 58 in the Electronic Equipment & Parts industry. It highlights the company's P/E ratio of 107.76, noting it is below its recent high but above its recent low. The article indicates that relevant data for P/B, P/S, and P/CF ratios have not yet been disclosed by the company.
G2 Investment Partners Management LLC's Novanta Inc(NOVT) Holding History
This article details G2 Investment Partners Management LLC's historical holdings in Novanta Inc (NOVT). As of March 31, 2026, G2 Investment Partners held 85,950 shares of NOVT, valued at $10.15 million, representing 2.5% of their portfolio. The firm has an estimated gain of $2.07 million (18.33%) on its NOVT investment based on the current stock price.
Novanta Inc (NOVT) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a revenue breakdown for Novanta Inc (NOVT), focusing on regional contributions rather than business segments, as business segment data is not yet disclosed. It details the company's revenue proportion from the United States, Rest of Europe, Germany, Rest of Asia-Pacific, and China. The financial data provided specifies revenue figures for recent fiscal years by region, highlighting the United States as the largest contributor.
Novanta Inc (NOVT) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Novanta Inc (NOVT), highlighting its current earnings forecast score of 9.33, ranking 1st in its industry. Analysts maintain a "Strong Buy" rating for NOVT, with an average price target of $158.50. The article also details expected revenue and EPS for upcoming quarters and past performance, alongside a peer comparison.
Novanta Inc (NOVT) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Novanta Inc (NOVT), outlining its major institutional holders and their proportions. It provides data on shareholdings by various types of investors, institutional activity over several quarters, and major shareholder changes. The report also lists ETFs that hold NOVT shares.
Novanta Inc (NOVT) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Novanta Inc's (NOVT) dividend and stock split history. It indicates that Novanta Inc has distributed 0.00 USD in dividends over the past five years and that there is no data available for historical stock splits. The page also includes current stock information for NOVT, such as its market capitalization and P/E ratio.
How (NOVT) Movements Inform Risk Allocation Models
This article analyzes Novanta Inc. (NASDAQ: NOVT) using AI models, indicating a neutral near and mid-term outlook with a long-term positive bias. It identifies an exceptional risk-reward short setup and outlines three institutional trading strategies: Position Trading, Momentum Breakout, and Risk Hedging. The analysis provides key support and resistance levels across different time horizons.
Novanta to acquire Riverpoint Medical for $1.5B
Novanta is set to acquire Riverpoint Medical from Arlington Capital Partners for $1.5 billion. This acquisition highlights the continued interest from strategic buyers in private equity-backed medical technology companies. The deal was announced on Tuesday.
Novanta Announces $300 Million Private Share Placement
Novanta has announced a private placement of 2,142,857 common shares at $140 per share, aiming to raise $300 million. This move is expected to slightly dilute existing shareholders and is part of the company's strategy to strengthen its balance sheet and maintain funding flexibility through private capital markets. While analysts have issued a Buy rating with a $180 price target, TipRanks' AI Analyst Spark rates NOVT as Neutral due to high valuation and technically extended conditions, despite a strengthened balance sheet and positive earnings momentum.
Novanta to acquire Riverpoint Medical in $1.45B deal, raises $300M privately
Novanta announced its acquisition of Riverpoint Medical for $1.45 billion, a move financed in part by a $300 million private placement. This strategic acquisition is set to expand Novanta's market presence and product offerings. The deal highlights significant M&A activity in the medical technology sector.
Novanta Announces $300 Million Private Share Placement
Novanta (NOVT) has announced a private placement of 2,142,857 common shares to institutional investors at $140 per share, raising approximately $300 million in gross proceeds. This deal, expected to close around June 11, 2026, will modestly dilute existing holders, increasing the total share count to roughly 42.5 million. Analysts currently rate NOVT as a "Buy" with a $180 price target, while TipRanks' AI Analyst, Spark, assigns a "Neutral" score due to high valuation and elevated technical conditions despite a strengthened balance sheet.
Novanta Inc. Announces Acquisition of Riverpoint Medical
Novanta Inc. has announced the acquisition of Riverpoint Medical for an upfront cash consideration of $1.2 billion and a milestone payment of $250 million in Q1 2027. This acquisition is expected to accelerate Novanta's strategic direction, expand its portfolio into high-growth minimally invasive surgery, and double its recurring medical consumables revenue. The transaction is projected to be immediately accretive to Novanta’s revenue growth, Adjusted Gross and EBITDA margins, Adjusted Diluted EPS, and Operating Cash Flows, with closing expected in Q3 2026.
NOVT News | NOVANTA INC (NASDAQ:NOVT)
This article provides a list of recent news and analysis for Novanta Inc. (NASDAQ:NOVT), including its stock performance and various company announcements. Key updates include passing a quality screen, beating Q1 estimates, announcing a $300 million private placement, and acquiring Riverpoint Medical. The news also highlights Novanta's upcoming presentations at healthcare and technology conferences.
Novanta (NASDAQ: NOVT) to raise $300M in private share placement
Novanta Inc. has announced a private placement of 2,142,857 common shares to institutional and accredited investors at $140.00 per share, aiming to raise approximately $300 million. The closing is expected around June 11, 2026, subject to customary conditions. The company has also entered into a Registration Rights Agreement to register the resale of these shares, which were sold in an unregistered transaction relying on Section 4(a)(2) of the Securities Act.
Portland medical device maker acquired by Novanta for $1.2B
Boston-based Novanta is set to acquire Riverpoint Medical, a Portland medical device maker, for $1.2 billion. The acquisition involves all outstanding equity interests of Riverpoint's parent company, Arlington Capital Partners.
Novanta (NOVT) to Acquire Riverpoint Medical for $1.45B
Novanta Inc. (NOVT) announced an agreement to acquire Riverpoint Medical for $1.45 billion, aiming to boost recurring revenue and strengthen its medical OEM partnerships. The deal includes an upfront payment and a future milestone payment, and Novanta secured $300 million through a private share placement. Despite this strategic move, Novanta's stock saw a pre-market dip, reflecting investor reaction to its high P/E ratio and recent insider selling.
Novanta to Acquire Riverpoint Medical from Arlington Capital Partners in $1.45 Billion Deal
Novanta Inc. will acquire Riverpoint Medical from Arlington Capital Partners for up to $1.45 billion, aiming to boost its presence in minimally invasive surgical consumables and increase recurring medical revenue. The deal, expected to close in Q3 2026, includes an initial cash payment of $1.2 billion and a $250 million milestone payment in 2027. This acquisition is projected to double Novanta’s recurring medical consumables revenue to approximately $300 million and expand its medical end-market exposure to about 60% of total revenue by focusing on Riverpoint's expertise in surgical fibers and implantable technologies.
Novanta to acquire Riverpoint Medical in $1.45B deal, raises $300M privately
Novanta (NOVT) has announced it will acquire Riverpoint Medical for $1.45 billion in cash. To help finance the deal, Novanta is raising $300 million through a private placement of common stock from several institutional investors. The acquisition is expected to close in Q3, subject to regulatory approvals.
Novanta Inc. Announces $300 Million Private Placement
Novanta Inc. has announced a private placement of its common shares, expected to raise approximately $300 million in gross proceeds before fees. The company will sell 2,142,857 common shares at $140.00 per share to institutional and accredited investors, with the closing anticipated around June 11, 2026. This transaction is a private offering and includes a registration rights agreement for the resale of the shares.
Novanta Inc. Announces $300 Million Private Placement
Novanta Inc. has announced a private placement of common shares to institutional and other accredited investors, expected to generate approximately $300 million in gross proceeds. The company will sell 2,142,857 common shares at $140.00 each, with the transaction anticipated to close around June 11, 2026. A registration rights agreement has also been executed to facilitate the resale of these unregistered shares.
Novanta Inc. Announces Acquisition Of Riverpoint Medical
Novanta Inc. has announced its acquisition of Riverpoint Medical. This news, reported by Reuters and Refinitiv, is a brief update on the company's corporate activities. The article indicates it's less than a minute read.
Novanta (NASDAQ: NOVT) to acquire Riverpoint Medical in $1.45B cash deal
Novanta (NASDAQ: NOVT) is set to acquire Riverpoint Medical for an upfront cash payment of $1.2 billion, plus a $250 million milestone payment expected in early 2027, totaling $1.45 billion. This strategic acquisition is intended to significantly expand Novanta's presence in minimally invasive surgical consumables, doubling its recurring medical consumables revenue to approximately $300 million and increasing medical end-market exposure to about 60% of total sales. The transaction is projected to be immediately accretive to Novanta's Adjusted Diluted EPS in 2026 and generate over $80 million in cumulative profit and capex synergies over five years.
Novanta Inc. Announces Acquisition of Riverpoint Medical
Novanta Inc. (NASDAQ: NOVT) has announced a definitive agreement to acquire Riverpoint Medical for an upfront cash consideration of $1.2 billion and a $250 million milestone payment, with the transaction expected to close in Q3 2026. This acquisition aims to accelerate Novanta's strategic direction, expand its portfolio into high-growth minimally invasive surgical consumables, and is projected to double its recurring medical consumables revenue. The deal is expected to be immediately accretive to Novanta's adjusted diluted EPS in 2026 and other financial metrics in 2027.
Novanta Inc stock (CA67000B1040): No dated news trigger found
This article states that no recent, dated news trigger was found for Novanta Inc. (CA67000B1040). Consequently, a comprehensive stock article based on source-backed facts cannot be built. The report emphasizes that without dated filings, press releases, or other verifiable updates, any further detail beyond general company description would be speculative, concluding that the current evidence is too thin for a news-driven market story.
Redwire, Universal Logistics, and Novanta Shares Skyrocket, What You Need To Know
Shares of Redwire (RDW), Universal Logistics (ULH), and Novanta (NOVT) surged after a recovery in the industrial sector, driven by broad market rebound and AI-driven capital expenditure commitments, notably AMD's £2 billion investment in the UK for AI research. Easing Middle East tensions also contributed to the sector's recovery by reducing energy prices. The article highlights that Universal Logistics, despite its recent gains, is still trading significantly below its 52-week high, with previous volatility driven by falling crude oil prices and reduced supply chain risks.
Novanta Inc. (NOVT) Presents at Jefferies Global Healthcare Conference 2026 - Slideshow
Novanta Inc. (NOVT) presented a slide deck at the Jefferies Global Healthcare Conference 2026. The presentation materials were made public on June 5, 2026. SA Transcripts, Seeking Alpha's transcripts team, published the article outlining this event.
Trading Systems Reacting to (NOVT) Volatility
This article from Stock Traders Daily discusses Novanta Inc. (NASDAQ: NOVT) volatility, indicating a near-term neutral sentiment amidst mid and long-term strength. It outlines various AI-generated trading strategies including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis to guide investors. The report suggests potential upside due to the absence of resistance levels above the current price.
Novanta (NOVT) CEO sells 6,500 shares in Rule 10b5-1 plan trades
Novanta Inc. CEO Matthijs Glastra sold 6,500 shares of common stock on June 2, 2026, through multiple open-market transactions ranging from $164.61 to $171.28 per share. These sales were conducted under a pre-established Rule 10b5-1 trading plan adopted on September 11, 2025. Following these sales, Glastra directly owns 42,723 shares and indirectly holds 54,382 shares via the Matthijs Glastra 2021 Irrevocable Trust.
1492 Capital Management LLC Takes Position in Novanta Inc. $NOVT
1492 Capital Management LLC initiated a new position in Novanta Inc. (NASDAQ:NOVT) during the fourth quarter, purchasing 10,506 shares valued at $1.25 million. Other institutional investors also increased their holdings, with institutions and hedge funds now owning 98.35% of Novanta's stock. The company's recent earnings exceeded expectations, and analysts maintain an average "Hold" rating with a $173 price target.
Novanta Inc. (NOVT) Presents at 46th Annual William Blair Growth Stock Conference - Slideshow
Novanta Inc. (NOVT) presented at the 46th Annual William Blair Growth Stock Conference. The company published a slide deck for this event. The article was written by the Seeking Alpha transcripts team, which handles numerous quarterly earnings call transcripts.
Mawer Investment Management Ltd. Buys 66,012 Shares of Novanta Inc. $NOVT
Mawer Investment Management Ltd. significantly increased its stake in Novanta Inc. by 16.9% in the fourth quarter, purchasing 66,012 additional shares and bringing its total holding to 457,160 shares valued at approximately $54.4 million. Despite insider selling by Novanta's CFO and CEO totaling about $3.1 million, the company demonstrated solid performance by beating quarterly EPS and revenue estimates, and subsequently raising its guidance. Analysts currently maintain a "Hold" rating on Novanta with an average price target of $173.
